Apelin, the Exercise Hormone That Cannot Decide Whose Side It Is On

#1

A Chinese review team at Xiangya Hospital has assembled the case that apelin, a small peptide hormone released by fat and muscle tissue that declines steadily with age, sits at a control point for three of the most common age-related musculoskeletal diseases. The verdict is not uniform. Apelin appears protective in skeletal muscle, where it drives mitochondrial biogenesis, autophagy and satellite cell function through AMPK and Akt signalling. It appears protective in bone, where it pushes stem cells toward osteoblast fate and suppresses osteoclast activity. But in joint cartilage it appears actively harmful, elevated in the synovial fluid of osteoarthritis patients and driving cartilage-degrading enzymes and unwanted blood vessel growth. The review is a narrative synthesis of 157 references.

Every few years the longevity field settles on a new circulating factor that seems to know how old you are. Apelin is one of the older candidates and one of the more stubborn ones, because it keeps producing results that point in opposite directions depending on which tissue you look at.

Apelin is a short peptide released by fat cells, muscle fibres and endothelium, and it acts through a G protein-coupled receptor called APJ. Its levels fall with age in both humans and rodents. Exercise raises it acutely. Because of this, it has been described as an exerkine, one of the chemical messengers through which physical activity communicates its benefits to the rest of the body.

The new review from Xiangya Hospital, published in Aging and Disease, does something useful by putting the muscle, joint and bone literature side by side rather than in separate silos. When you do that, a problem appears. In muscle, the story is clean and encouraging. Mice lacking apelin or its receptor age badly and lose muscle function early. Restoring apelin in old mice improves muscle mass, strength and the regenerative capacity of muscle stem cells, apparently by switching on the same machinery exercise switches on: mitochondrial biogenesis, cellular housekeeping through autophagy, and suppression of inflammatory signalling.

In bone, the picture is mostly favourable but noisier. Apelin nudges bone marrow stem cells toward becoming bone-building osteoblasts, and it restrains the osteoclasts that dissolve bone. Yet mice engineered to lack fat-derived apelin have more bone, not less, which is the opposite of what a simple protective model predicts.

In cartilage, apelin looks like a villain. It is elevated in arthritic joints, it stimulates the enzymes that chew through cartilage matrix, and it promotes the blood vessel growth that accompanies joint degeneration.

The uncomfortable implication is that a systemic apelin drug might strengthen your muscles and your bones while accelerating the destruction of your knees. That is a tissue-targeting problem, not a dosing problem, and the review is candid that nobody has solved it.

Human data are thinner still. Several clinical studies cited here found no relationship at all between circulating apelin and sarcopenia or bone strength, and at least one found apelin elevated rather than depressed in sarcopenic patients. The authors suggest that in advanced disease the body may compensate by raising apelin, which would mask the underlying decline. That is a reasonable guess. It is also, as stated, untestable. None of this makes apelin uninteresting. It makes it early.

Context and Source

  • Open Access Paper: Apelin: A Promising Therapeutic Target for Degenerative Diseases of the Musculoskeletal System
  • Authors: Jinkun Xu, Hengzhen Li, Jianfeng Sun, Gaoming Liu, Yuming Yao, Dongliang Yuan, Wenfeng Xiao, Yusheng Li
  • Institution: Department of Orthopedics, Xiangya Hospital, Central South University, and the National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, China
  • Journal: Aging and Disease, Volume 17, Number 5, pages 2529 to 2543, October 2026.
    Article type: Narrative review
  • Impact evaluation: Published metrics for Aging and Disease vary by source,Taking the mid-range figure of roughly 7 to 9.6: the impact score of this journal is approximately 7 to 9.6, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal within its specialty

Related Reading: